Background Haemophilia B is caused by genetic aberrations in the F9 gene. The majority of these are non-synonymous mutations that alter the primary structure of blood coagulation factor IX (FIX). However, a synonymous mutation c.459G>A (Val107Val) was clinically reported to result in mild haemophilia B (FIX coagulant activity 15%-20% of normal). The F9 mRNA of these patients showed no skipping or retention of introns and/or change in mRNA levels, suggesting that mRNA integrity does not contribute to the origin of the disease in affected individuals. The aim of this study is to elucidate the molecular mechanisms that can explain disease manifestations in patients with this synonymous mutation. Methods We analyse the molecular mechanisms underlying the FIX deficiency through in silico analysis and reproducing the c.459G>A (Val107Val) mutation in stable cell lines. Conformation and non-conformation sensitive antibodies, limited trypsin digestion, activity assays for FIX, interaction with other proteins and posttranslation modifications were used to evaluate the biophysical and biochemical consequences of the synonymous mutation. Results The Val107Val synonymous mutation in F9 was found to significantly diminish FIX expression. Our results suggest that this mutation slows FIX translation and affects its conformation resulting in decreased extracellular protein level. The altered conformation did not change the specific activity of the mutated protein.
INTRODUCTION
We and others have previously shown that synonymous mutations can affect protein folding, structure and function. 1 Synonymous mutations can affect protein biogenesis via multiple mechanisms, including affecting the efficiency of protein expression and/or protein folding. [2] [3] [4] [5] [6] [7] Although no change in mRNA integrity was reported for these patients, a change in mRNA structure may have led to altered protein translation dynamics and reduced protein levels. Codon usage can affect translational speed; frequently used codons are translated more rapidly than infrequently used ones. [8] [9] [10] Modulation of local elongation rates through synonymous mutations has been shown to affect protein secretion, 11 thus it is possible that improper processing contributes to differences in protein expression, conformation and stability. It is likely that the multitude of mechanisms by which synonymous mutations alter protein structure and function have clinical consequences because a critical mass of literature shows that synonymous mutations are associated with numerous human diseases. [12] [13] [14] Haemophilia B is a blood clotting disorder caused by mutations in the F9 gene, which encodes a serine protease in the blood coagulation system known as factor IX (FIX). 15 Mutations in F9 may lead to severe (FIX coagulant activity (CA) <1% of normal), moderate (CA 1%-5%) or mild (CA 5%-30%) haemophilia B. 16 A synonymous mutation, c.459G>A (GTG>GTA, p.Val153Val or Val107Val (amino acid number after the cleavage on secretion)) had been identified in five non-related patients with mild haemophilia B, resulted in a ∼80% reduction in FIX CA. 15 Studies of lymphocyte F9 mRNA in these five individuals showed no skipping or retention of introns and/or change in mRNA levels, suggesting that mRNA integrity does not contribute to the origin of the disease.
FIX is a vitamin K-dependent blood coagulation factor that converts factor X (FX) to its active form. FIX is synthesised as a 461 amino acid precursor ( primarily in the liver) and then secreted into plasma. FIX zymogen undergoes extensive cotranslational and post-translational modifications, including but not limited to, glycosylation (∼17% carbohydrate by weight) and γ-carboxylation. 17 It has a 46 amino acid N-terminal propeptide (which includes a 28 amino acid signal sequence) that is cleaved. FIX circulates in the plasma as a single chain inactive zymogen of 415 amino acids. During blood clotting, it is activated by two distinct mechanisms including either factor XIa (FXIa) (the intrinsic pathway) or factor VIIa (FVIIa)/tissue factor (the extrinsic pathway). The activation of FIX results in the excision of the so-called activation peptide (amino acid 145-180) that converts FIX into its active form (FIXαβ), where the chains are linked together by a disulfide bond.
In the current study, we have used a combination of in silico, in vitro and ex vivo (cellular) systems to understand the potential molecular mechanism(s) by which FIX c.459G>A (Val107Val) mutation causes reduction in FIX protein activity in the patient's plasma. 15 The valine at position 107 is located at the beginning of the second β-sheet in the antiparallel among five tandem β-sheet structure of the second epidermal growth factor (EGF)-like domain with average conservation score 18 (http://consurftest.tau.ac.il/). This Val107Val mutation is 1 of 10 identified synonymous variants that are clinically associated with haemophilia B. Our studies revealed that FIX c.459G>A (Val107Val) mutation affects FIX synthesis, maturation and conformation, therefore leading to FIX deficiency in the patient's plasma.
MATERIALS AND METHODS Computational analyses
The F9 mRNA sequence (RefSeq NM_000133.3) and 151 nucleotide fragment centred on the c.459G>A were analysed with mfold (http://unafold.rna.albany.edu/?q=mfold), 19 Kinefold (http://kinefold.curie.fr/) 20 and NUPACK (http://www.nupack. org/) 21 software programmes. Relative synonymous codon usage (RSCU) and Codon Adaptation Index (CAI) were calculated as previously described. 10 
In vitro translation
In vitro translation of the in vitro transcribed F9 mRNAs was performed in the presence of [
35 S]-Met following standard procedures with rabbit reticulocyte lysate (RRL) system (Promega) supplemented with calf liver tRNAs.
Ex vivo expression vectors
Wild-type F9 ORF with a truncated intron 1, originating from the pCI-neo-hFIX1b vector bearing human F9 cDNA, was subcloned into pcDNA3.1/V5-His-TOPO (Invitrogen/Life Technologies). The c.459G>A (Val107Val) variant was constructed by site-directed mutagenesis using QuikChange II XL kit (Stratagene/Agilent Technologies).
Cell culture and transfection
Human HEK293 cells and Huh-7 cells were transformed using FuGENE 6 Transfection Reagent (Roche Diagnostics). Stable cell lines were created under selection pressure using Geneticin. The transfection conditions were tuned to present relatively low expression so slight differences between the wild-type and mutant will be detected.
RNA isolation and quantitative RT-PCR
Total RNA was isolated by Qiagen RNeasy Kit following manufacturer's protocol with an additional 15 min on-column DNase incubation step. F9 mRNA expression levels were measured against the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) reference gene using real-time quantitative RT-PCR. F9 cDNA was obtained by reverse transcription (Roche Diagnostics) followed by PCR amplification.
Polyacrylamide gel electrophoresis, immunoblotting analysis, ELISA and activity measurements Media concentration and cellular extracts were prepared as described earlier. 22 Extracellular and intracellular protein expression were quantified via western blot analysis under denaturing and native conditions 23 and/or FIX-specific ELISA (Invitrogen/Thermo Fisher Scientific). Western blot analysis was performed using anti-V5 antibody (catalogue #R960-CUS, Invitrogen/Thermo Fisher Scientific), antihuman FIX antibodies (ESN1, American Diagnostica; AHIX-5041, Haematologic Technologies; 9D (catalogue #sc-59503), Santa Cruz Biotechnology and GMA-138 (catalogue #sc-65952), Santa Cruz Biotechnology), anti-FIX propeptide antibody (a gift from Dr Peters, Biogen) or antihuman GAPDH antibody (catalogue #sc-47742, Santa Cruz Biotechnology), horseradish peroxidase conjugated antimouse secondary antibody (catalogue #31340, Thermo Fisher Scientific) and horseradish peroxidase conjugated antirabbit secondary antibody (catalogue #611-1302, Rockland). All the primary antibodies are derived from mouse monoclonal except for the propeptide antibody which is rabbit polyclonal.
Media was resolved by size-exclusion chromatography using a Superdex 200 column. Activated partial thromboplastin time (aPTT) assay was performed with TriniCLOT Automated aPTT (Trinity Biotech), FIX-deficient plasma (HRF) and international standard FIX (#07/182, NIBSC) by an ACL Elite Pro system (Instrumentation Laboratory Company). Chromogenic assay was performed using a commercial kit (Biophen) and measured by Victor X3 plate reader (PerkinElmer) at 405 nm.
Protein purification, limited proteolysis and mass spectrometry analysis
Media from FIX expressing stable cell lines was collected for 3-4 days, concentrated 10-fold and subjected to His-tag FIX affinity purification using cobalt resin (Talon, Clontech). The eluted protein was dialysed against 150 mM NaCl, 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer. Supernatant was filtered through Pall Acropak filters (0.2 mm, Pall, Port). Cell culture harvest was directly loaded onto an immobilised metal ion affinity chromatography HiTrap column. Proteins were eluted with 20 column volumes linear gradients (0%-100%) of a 25 mM HEPES, 500 mM NaCl and 250 mM imidazole buffer. The eluate was then dialysed using a 10 kDa membrane against the 10 mM HEPES, 150 mM NaCl buffer. Protein was separately purified for circular dichroism (CD) analysis with a V5-tagged purification kit (MBL International) as per manufacturer's protocol.
The integrity of purified protein was verified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by silver staining (Invitrogen/Thermo Fisher Scientific) (figure 2A). Purified proteins were subjected to limited proteolysis with increasing trypsin concentrations (Sigma-Aldrich) (0, 0.002, 0.005 and 0.009 mg/mL) for 5 min at 37°C. Digestion was terminated by adding SDS-sample buffer and boiling the samples for 20 min at 100°C. Samples were analysed by western blotting with anti-human FIX antibody ESN1.
Activation by FXIa
Purified FIX (1 mM) was incubated with FXIa (2 nM) in 20 mM HEPES ( pH 7.4), 150 mM NaCl, 0.2% polyethylene glycol (PEG) and 5 mM calcium. At-timed intervals samples were removed and added to EDTA and lima bean trypsin inhibitor (LBTI, 250 mg/mL) to inhibit FXIa. LBTI does not inhibit FIXa. The amount of FIXa was assessed as the ability to cleave Pefachrome FIXa. The relative rate of substrate cleavage is plotted against the time.
FIXa active site titration
Purified FIXa was incubated with the indicated concentration of antithrombin with 5 U/mL heparin in 20 mM HEPES, 150 mM NaCl and 0.2% PEG for 2 hours. The amount of FIXa was assessed as the ability to cleave Pefachrome FIXa. The rate of substrate cleavage is plotted against the concentration of antithrombin. Since FIXa forms a one to one complex with antithrombin, the amount of antithrombin required to completely inhibit FIXa activity is equal to the amount of FIXa.
FX activation by the FIXa/FVIIIa complex
Buffer for these studies was 20 mM HEPES ( pH 7.4), 150 mM NaCl, 0.2% PEG, 5 mM calcium chloride. The indicated concentration of FIXa was incubated with 0.4 nM FVIIIa, 40 mM phospholipid vesicles and 170 nM FX. FVIII was activated with thrombin; subsequently the thrombin was inhibited with hirudin. Phospholipid vesicles were phosphatidylcholine:phosphatidylethanolamine:phosphatidylserine 41:44:15, a composition designed to mimic the lipid composition of highly activated platelets. At-timed intervals samples were removed and the amount of FXa was assessed as the ability to cleave Pefachrome FXa. The rates of substrate cleavage were plotted against time and the rate of FX activation was determined as the slope of the data fit. The rate of FX activation was plotted against the FIXa concentration.
Lys-C peptide mapping
Based on Peters et al, 24 50 mg FIX samples were vacuum dried and denatured with 50 mL with 6 M guanidine-HCl-150 mM Tris-HCl-2.5 mM EDTA (pH 8.0); 1 mL of dithiothreitol (1 M) was added and incubated at 37°C for 30 min to reduce the sample; 6 mL of iodoacetamide (0.5 M) was added and incubated in the darkness at room temperature for 30 min. FIX samples were then buffer exchanged into 50 mM Tris-HCl (pH 7.2) using Micro Bio-Spin column (Bio-Rad). The sample was digested with 5 mL of 0.5 mg/mL Lys-C (Wako Chemicals USA) at 25°C for 3 hours and then quenched by adding 1 mL of 10% trifluoroacetic acid. The 15 mg of digested sample was analysed by "liquid chromatography-ultraviolet-mass spectrometry-mass spectrometry". Originally it was "LC-UV-MS/MS". (Agilent 1290 UPLC coupled with Thermo LTQ linear ion trap mass spectrometer). The resulting peptides were identified and confirmed by MS and MS/MS, for both sequence and post-translational modifications.
Circular dichroism
CD was measured by JASCO J-810 CD spectropolarimeter, equipped with a Peltier temperature-controlled cell holder. Each spectrum (representing the sum of five separate accumulations) was measured with a 0.1 cm path length cell at 5°C with a 10 nm/min scanning speed and wavelength range (190-260 nm). CD spectra were evaluated at a concentration range of 0.4-0.7 mg/mL. Thermal unfolding and refolding experiments of the FIX protein were conducted from 5 to 55°C (measurements at 10°C intervals; approximately 12 min per interval) and cooled to 5°C. FIX secondary structure content was estimated by Dichroweb software (http://dichroweb.cryst.bbk.ac.uk/html/ home.shtml).
N-Acetyl-leucyl-leucyl-norleucinal treatment
Stable FIX expressing clones were treated with cycloheximide (10 mg/mL) (Sigma-Aldrich) and subsequently by N-acetylleucyl-leucyl-norleucinal (ALLN), an inhibitor of neutral Ca 2+ -dependent cysteine proteases, calpain and the proteasome 25 (Sigma-Aldrich) at a 20 mg/mL concentration, 30 hours prior to harvesting (control wells were treated with dimethyl sulfoxide). Protein expression was analysed by western blotting and ELISA.
Glycosylation assessment of purified FIX
The wild-type and Val107Val purified FIX proteins (1.5 mg/reaction) were treated with the commercial mix of PNGase F, endo-O-glycosidase, α-2-neuraminidase, β-1,4-galactosidase and β-N-acetylglucosaminidase at 37°C for 15 min (EDEGLY Enzymatic Protein Deglycosylation Kit, Sigma). After termination of the reaction by adding loading dye solution, the reaction mixtures were run on 8% Bis-Tris SDS-PAGE western blot analysis using antihuman FIX antibody (9D). The commercially available plasma-derived FIX (Mononine, CSL Behring, a gift from Dr Mikhail V Ovanesov, Food and Drug Administration) and recombinant FIX (BeneFIX Wyeth Pharmaceuticals) were used as positive controls.
RESULTS
The ∼80% reduction of FIX CA observed in plasma of patients with haemophilia B with the c.459G>A (Val107Val) mutation can be explained by a number of plausible mechanisms, which could include effects on both mRNA and protein levels. Analysis of F9 mRNA in affected individuals showed that changes in mRNA expression levels and/or its integrity do not contribute to FIX deficiency in affected individuals. 15 These data suggest that FIX deficiency in patients likely arise due to (i) reduced translation of mRNA, caused by a c.459G>A (Val107Val) mutation, leading to reduced protein expression levels and (ii) reduced protein stability, secretion efficiency and/ or activity due to changes in FIX conformation and/or altered post-translational modifications and/or all of the above. We addressed these possibilities by employing a combination of in silico, in vitro and ex vivo approaches.
Effects of synonymous FIX Val107Val mutation on F9 mRNA structure, codon usage and thermodynamic stability Three computational algorithms (mfold, Kinefold and NUPACK) were used to assess the effect of the c.459G>A (Val107Val) mutation on mRNA structure, showed a moderate reduction in mRNA thermodynamic stability (see online supplementary figure S1a-c). Although decreased mRNA thermodynamic stability generally leads to increased protein expression levels, we found that in vitro translation involving the c.459G>A mutant yields 25%-30% less protein ( figure  1A ). This suggests that the mutation moderately reduces global translation rates; however, this result does not clarify the significance of its decreased mRNA thermodynamic stability. Measures of codon usage, the RSCU and CAI, 10 show that the GTA codon is substantially less frequently used in humans than GTG (table 1) . Owing to a decrease in codon usage frequency, a decrease in translation efficiency would be expected in the mutant, but a single codon substitution generally would not be expected to lead to a drastic change in translation and it cannot account for the ∼80% lower FIX activity in patients. These data suggest that additional mechanism(s) are responsible for decreased FIX activity in patients.
Ex vivo analysis of FIX Val107Val mutation on FIX expression
To further investigate changes in protein structure/function due to the c.459G>A mutation, we compared the levels and activity of wild-type and variant proteins expressed in HEK293 and Huh-7 stably transfected cell lines, which were constructed to have equivalent levels of mRNA (figure 1B). mRNA was examined for its integrity and sequencing reveals no unexpected splicing events in these systems (see online supplementary figure S2). Expression of FIX was monitored using a set of specific antibodies. Compared with wild-type, expression of mutant FIX was significantly lower in both cell lines regardless of whether FIX was identified in the medium (extracellular) or in the cell lysate (intracellular). The c.459G>A (Val107Val) mutation resulted in a 40%-80% reduction in the amount of secreted protein ( figure 1C) . Moreover, equal amounts of the total secreted protein from media collected from an equal number of cells were subjected to size exclusion chromatography followed by ELISA. Lower levels of mutant FIX (in comparison with wild-type) were found in all fractions ( figure 1D ). The decreased level of Val107Val FIX protein in the media was reflected by activity measurements, showing diminished levels (∼45% of wild-type FIX, figure 1E ) of activity, resulting in comparable specific activity (figure 1F).
A 'silently' mutated FIX Val107Val protein exhibits an altered conformation
We showed above that the c.459G>A (Val107Val) mutation results in lower expression of FIX protein. Non-synonymous mutations (altering protein structure) in the second EGF-like domain (where Val107Val mutation is located) were shown to cause impaired intracellular processing and secretion. 26 Current knowledge about the effects of synonymous mutations on protein function suggests that they can also alter protein structure. Therefore, we decided to further probe protein structure and investigate protein processing.
First, we investigated the global secondary structure of the mutant protein by CD. Both wild-type and Val107Val were found to have similar secondary structure content, with minor variation seen among replicate measurements (see online supplementary figures S3 and S4). Thermal unfolding and refolding experiments also indicated that both wild-type and mutant FIX share similar thermal stability (see online supplementary figure S3). These results are consistent with the prevailing consensus that synonymous mutations are usually not associated with a change in secondary protein structure of a protein.
Second, we investigated binding of conformation-sensitive antibodies to equal amounts of purified protein, because antibodies are often sensitive to proteins' conformation changes. Immunoblots on equal amounts of purified FIX using six antibodies are depicted in figure 2 . Under denaturing conditions, immunoblotting with monoclonal anti-FIX antibody ESN1 showed comparable FIX bands for both variants ( figure 2B) ; however, a stronger signal for the wild-type protein was observed under native conditions ( figure 2C ). The use of antibodies 9D and GMA-138 revealed weaker signal for Val107Val variant under denaturing conditions, while weaker signal for the wild-type variant was observed under native conditions. A high molecular band was always observed in the native gel systems, 23 but the intensities of the high molecular weight complexes (upper band) consistently correlate with the intensities of the lower band regardless of ratio of the lower bands between wildtype and Val107Val FIX variants (data not shown). These results In all graphs, data represent the mean±SD of at least three independent experiments. n.s., not significant.
suggest that conformational changes in the variant may alter the accessibility of the anti-FIX epitopes and are consistent with limited trypsin proteolysis, which shows that the mutant has a greater sensitivity to trypsin ( figure 2D) .
Enhanced sensitivity to trypsin digestion also suggests that the Val107Val FIX protein may be prone to increased intracellular degradation. However, the use of a cellular proteasome inhibitor (ALLN) resulted in similar stabilisation of both proteins ( figure 2E ).
Detailed functional characterisation
While we found the specific activity of purified wild-type and Val107Val FIX to be similar, the Val107Val mutant protein clearly exhibits altered conformation as shown through differential immunoreactivity. Interestingly, the crystal structure of FIX (2WPJ.pdb) indicates that valine 107 is found in a region critical for an interaction with FVIII [27] [28] [29] and Val107Ala nonsynonymous mutation reduces FIX-specific activity due to elevated Km to FVIII. 30 Moreover, 5 of 10 clinically associated synonymous FIX mutations, in 3 amino acid codons, are in the second EGF-like domain ( figure 3 ). Valine 107 may therefore be positioned in a region sensitive to changes in translation rate, and subsequently to a subtle change in the structure. Therefore, we tested whether interaction with other proteins in the coagulation cascade were affected. The various properties examined included (a) the rate of activation by FXIa and (b) the relative effect of the cofactor FVIIIa on the FIXa activity. The results obtained from these assays are presented in figure  4 , and in all cases, they yielded similar value for the wild-type and mutant FIX, suggesting that any difference in the conformation is subtle.
Val107Val FIX mutant does not exhibit significant difference in its composition and the extent of post-translational modifications, specifically γ-carboxylation Differences in conformation of the protein variants may arise as a result of the altered processing. It is also possible that critical FIX cotranslational and post-translational modifications such as γ-carboxylation and glycosylation could be altered in the mutant FIX protein, thus leading to differences in protein conformations. Mass spectrometric analysis of the purified FIX variants In all graphs, data represent the mean±SD of at least three independent experiments. n.s., not significant.
did not reveal any significant differences between wild-type and mutant proteins. The only notable difference was the relative proportion of propeptide ( pro-FIX) in the wild-type and mutant proteins: 9.5% and 20.7%, respectively (see online supplementary table S1a, and figure S5 ). Online supplementary table S2 lists the detected Gla peptides and the peptide containing Val107al (K9) in Lys-C peptide maps. The N-glycosylation and O-glycosylation in the activation peptide of FIX were not characterised in detail due to its complexity. From these results, it is likely that moderate differences in translation rates between the two variants may lead to the moderately altered processing and subsequent changes in the conformation of FIX. The glycosylation status of intracellular wild-type and Val107Val FIX proteins was also examined (see online supplementary figure S6).
No apparent difference was observed in deglycosylation pattern of these FIX proteins, although this method detects overall molecular weight and is not sensitive for detecting distinct glycosylation.
DISCUSSION
Here, we have investigated a synonymous mutation in F9 that is clinically associated with haemophilia B phenotype. 15 Our studies suggest that the observed decrease in FIX activity in affected individuals can be explained by moderately decreased efficiency of protein translation, leading to altered propeptide processing, causing subsequent changes in protein integrity and conformation and thus decreasing overall protein expression. These changes are not caused by a change in mRNA integrity, but rather originate from a change in the efficiency of mutant mRNA translation. Whereas numerous non-synonymous mutations in the F9 gene have been linked to haemophilia B, 31 this report provides insight into the mechanism(s) by which a single synonymous mutation can sufficiently disrupt the protein properties to cause the clinical manifestation of a bleeding disorder (figure 5). Early studies that explored the underpinnings of synonymous mutation-mediated effects on protein function 4 focused on single unique mechanisms. In this study, we demonstrate that a synonymous mutation can have a multitude of effects. As the clinical effect of this GTG>GTA mutation can be quantified vis-à-vis decrease in FIX activity, we show that the moderate decrease in protein translation alone is not sufficient to explain the substantial decrease in protein expression levels/activity and the clinical outcome. We also suggest that a specific location of the valine codon is one of the reasons, why the underlying Val107Val (GTG>GTA) mutation causes the disease. Effects of the synonymous codons are believed to be position dependent. In this particular case, the specific location of the mutation in the second EGF-like domain may be one of the major contributors to impaired post-translational modification(s) and overall extracellular protein levels. These are associated with subtle changes in its structure caused by altered translation dynamics (figure 3). Note that non-synonymous mutations in the second EGF-like domain were previously shown to cause FIX impaired intracellular processing and secretion. 26 We have previously presented an extensive review of the multiple mechanisms by which synonymous mutations affect protein structure and function and the methods that may be used to study these. 4 This study shows that these mechanisms may act in concert and it is important to exhaustively (and where possible quantitatively) characterise the mechanistic basis of clinical outcomes driven by synonymous changes. As a final note, it is important to point out that the synonymous change characterised in this study is not unique. At least nine additional synonymous mutations associated with haemophilia B are reported in the Centers for Disease Control and Prevention F9 mutation database (http://www.cdc.gov/ncbddd/hemophilia/ champs.html). Figure 5 Mechanism by which a single synonymous mutation can disrupt protein properties. FIX, factor IX.
